NDAORALSUSPENSION
Approved
Jun 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
TADLIQ (tadalafil) by Fosun Pharma is phosphodiesterase 5 inhibitors [moa]. Approved for erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension and 1 more indications. First approved in 2022.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TADLIQ is an oral tadalafil suspension approved in 2022 by Fosun Pharma as a phosphodiesterase-5 inhibitor. It treats multiple indications including erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, and lower urinary tract symptoms by inhibiting PDE5 to increase cyclic GMP levels and promote vasodilation.
$0.146BPart D
Peak12.6 years to LOEEarly-stage peak product with modest Part D penetration; brand team focus on indication expansion and market share capture in a competitive PDE5 space.
Mechanism of Action
Phosphodiesterase 5 Inhibitors
Pharmacologic Class:
Phosphodiesterase 5 Inhibitor
Indications (4)
Worked on TADLIQ at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.